LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
27 funds hold it · Insiders net selling
Net buying: insiders sold $7M and bought $35M on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 3, 2026
Period ending
Sep 30, 2026
Earnings per share
-$1.09 expected
Estimates as of Nov 9, 2026
EPS expected
-$0.77 to $0.11
Revenue expected
11 analysts
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 3, 2026 | $1.83est. -$1.09 | +$2.92beat | $431.3MSEC filing | +50.1%from $287.3M |
| Jun 30, 2026Reported Jul 30, 2026 | -$1.99est. -$2.23 | +10.76%beat | $364.3MSEC filing | +71.2%from $212.8M |
| Mar 31, 2026Reported May 6, 2026 | -$1.38est. -$4.14 | +66.70%beat | $311.3MSEC filing | +126.8%from $137.3M |
| Dec 31, 2025Reported Feb 19, 2026 | -$2.57est. -$0.88 | -$1.69miss | $321.1MAlpha Vantage | +210.8%from $103.3M |
| Sep 30, 2025Reported Nov 4, 2025 | -$4.96est. -$1.99 | -149.25%miss | $287.3MSEC filing | +362.0%from $62.2M |
| Jun 30, 2025Reported Aug 5, 2025 | -$1.90est. -$3.53 | +46.18%beat | $212.8MSEC filing | +1353.8%from $14.6M |
| Mar 31, 2025Reported May 1, 2025 | -$3.32est. -$3.79 | +12.40%beat | $137.3MSEC filing | No year-ago quarter |
| Dec 31, 2024Reported Feb 26, 2025 | -$2.71est. -$4.12 | +34.30%beat | $103.3MAlpha Vantage | No year-ago quarter |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $321.1M | $311.3M | $364.3M | $431.3M |
| Cost of what it sold | $24.4M | $26.8M | $40.0M | $37.8M |
| Gross profit | $296.6M | $284.5M | $324.2M | $393.5M |
| What it spent | ||||
| Research and development | $116.3M | $108.7M | $91.2M | $71.8M |
| Sales and admin | $209.1M | $268.5M | $289.4M | $265.7M |
| Other operating costs | $30.9M | — | — | — |
| Total operating expenses | $356.2M | $377.2M | $380.6M | $337.5M |
| What was left | ||||
| Operating profit | -$59.6M | -$92.7M | -$56.3M | $56.0M |
| Interest on debt | $8.3M | $7.8M | $7.9M | $8.1M |
| Profit before tax | -$58.6M | -$94.4M | -$57.9M | $55.4M |
| Net profit | -$58.6M | -$94.4M | -$57.9M | $55.4M |
| EBITDA | -$49.9M | -$86.2M | -$49.6M | $63.9M |
This stock is under pressure.
Trend
Under pressure
15 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Is Madrigal Pharmaceuticals (MDGL) Cheap Following Rezdiffra Data And A Swing To Net Income?
Leans bullishNov 10Madrigal Turns Profitable as Rezdiffra Sales Surge 50%
BullishNov 10MDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity Concerns
BearishNov 104 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
BullishNov 10MDGL Investors Have Opportunity to Join Madrigal Pharmaceuticals, Inc. Fraud Investigation with SBS Law
BearishNov 9What Does Madrigal Pharmaceuticals (MDGL) Whistleblower Probe Mean For Investors?
BearishNov 8Madrigal Pharmaceuticals general counsel Kelley sells $430,800 stock
NeutralNov 8Form 4 Madrigal Pharmaceuticals Inc: Shannon T. Kelley (General Counsel) For: 6 November By Investing.com
NeutralNov 735 macro signals shaping MDGL right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
